N-(cyclopropylmethyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide

ID: ALA3104413

PubChem CID: 54742334

Max Phase: Preclinical

Molecular Formula: C14H15N3O3S

Molecular Weight: 305.36

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1nc(-n2ccc(O)cc2=O)sc1C(=O)NCC1CC1

Standard InChI:  InChI=1S/C14H15N3O3S/c1-8-12(13(20)15-7-9-2-3-9)21-14(16-8)17-5-4-10(18)6-11(17)19/h4-6,9,18H,2-3,7H2,1H3,(H,15,20)

Standard InChI Key:  KMQBABMBEFDUTM-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 21 23  0  0  0  0  0  0  0  0999 V2000
   16.2751  -18.3212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.5783  -17.8874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5591  -17.0655    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7705  -16.8289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3082  -17.5083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8084  -18.1598    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   14.4972  -16.0588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4872  -17.5317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0543  -16.8360    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.0949  -18.2550    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.2333  -16.8595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8046  -16.1596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2404  -19.1421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9330  -19.5799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6614  -19.1966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6929  -18.3749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9960  -17.9366    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0253  -17.1158    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.3564  -19.6372    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.7816  -15.3401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0817  -15.7688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  4  1  0
  2  3  2  0
  4  5  2  0
  5  6  1  0
  6  2  1  0
  4  7  1  0
  5  8  1  0
  8  9  1  0
  8 10  2  0
  9 11  1  0
 11 12  1  0
  1 13  1  0
  1 17  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 15 19  1  0
 20 12  1  0
 21 20  1  0
 12 21  1  0
M  END

Associated Targets(Human)

FADS2 Tbio Fatty acid desaturase 2 (102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FADS1 Tchem Fatty acid desaturase 1 (145 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Caco-2 (12174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SCD Tchem Acyl-CoA desaturase (1011 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver microsome (4459 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scd1 Acyl-CoA desaturase 1 (352 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 305.36Molecular Weight (Monoisotopic): 305.0834AlogP: 1.45#Rotatable Bonds: 4
Polar Surface Area: 84.22Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 7.61CX Basic pKa: CX LogP: 0.96CX LogD: 0.75
Aromatic Rings: 2Heavy Atoms: 21QED Weighted: 0.90Np Likeness Score: -1.40

References

1. Sun S, Zhang Z, Raina V, Pokrovskaia N, Hou D, Namdari R, Khakh K, Ratkay LG, McLaren DG, Mork M, Fu J, Ferreira S, Hubbard B, Winther MD, Dales N..  (2014)  Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.,  24  (2): [PMID:24370012] [10.1016/j.bmcl.2013.12.035]

Source